DES has made stenting a successful treatment modality. Still problems exists such as late thrombosis and continued neo-intimal proliferation. Blood flow affects the drug retained in the stent and subsequently on the time frame of vascular healing. To find out drug release kinetics from DES implanted in two different flow conditions, DES were implanted in porcine carotid artery and coronary artery. The drug release kinetics was found out by estimating the drug retained in the stent at different time periods. Through this study it is shown that DES in the coronary artery has a T1/2 of 24 days compared to 2 days in the carotid artery. The difference in T1/2 is attributed to the difference in flow as estimated using Hagen-Poiseuille equation. Evaluation of DES through heterotopic implantation may yield false results due to flow discrepancy. Moreover flow conditions should also be considered while designing the drug matrix to have optimum clinical efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2007.07.111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High risk of drug-resistant tuberculosis in IGRA-negative contacts: should preventive treatment be considered?
Infection
January 2025
Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Parkallee 35, Borstel, Germany.
Purpose: Deciding whether to provide preventive treatment to contacts of individuals with multidrug-resistant (MDR) tuberculosis is complex.
Methods: We present the diagnostic pathways, clinical course and outcome of tuberculosis treatment in eight siblings from a single family. Tuberculosis disease was diagnosed by Mycobacterium tuberculosis culture and molecular detection of M.
Advances in the Release of Amide-Containing Molecules.
Chemistry
January 2025
University of Cambridge, Department of Chemistry, Lensfield Road, CB2 1EW, Cambridge, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
The ability to release a molecule from a larger construct in a controlled manner is of great importance to produce effective prodrugs, antibody-drug conjugates, and chemical probes. Amides are ubiquitous functional groups and yet methods to utilise them as molecular release handles are seldom reported. This concept article highlights the advances made in amide release strategies and how these approaches have been utilised.
View Article and Find Full Text PDFβ-Glucuronidase-Responsive Albumin-Binding Prodrug of Colchicine-Site Binders for Selective cancer Therapy.
ChemMedChem
January 2025
UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers, groupe « Systèmes Moléculaires Programmés », Faculté des Sciences Fondamentales et Appliquées, 4 rue Michel Brunet, TSA 51106, 86073, Poitiers, FRANCE.
The development of novel therapeutic strategies enabling the selective destruction of tumors while sparing healthy tissues is of great interest to improve the efficacy of cancer chemotherapy. In this context, we designed a β-glucuronidase-responsive albumin-binding prodrug programmed to release a potent Isocombretastatin A-4 analog within the tumor microenvironment. When injected at a non-toxic dose in mice bearing orthotopic triple-negative mammary tumors, this prodrug produced a significant anticancer activity, therefore offering a valuable alternative to the systemic administration of the parent drug.
View Article and Find Full Text PDFOptimizing voriconazole-loaded thermoresponsive hydrogel: tools and studies.
Drug Dev Ind Pharm
January 2025
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Objective: The present study aims to develop and evaluate the voriconazole-loaded thermoresponsive hydrogel using tools.
Methods: Poloxamer 407 and PEG 400 were selected as the components from studies for thermoresponsive hydrogel of voriconazole. The cohesive energy density (CED) and solubility parameters (SP) were calculated using Biovia Material Studio 2022 software to predict the polymer-polymer miscibility and drug-polymer miscibility.
Formulation and Evaluation of Lipid/Soluplus-Stabilized Nanocrystals of Paclitaxel and Bosutinib for a Synergistic Effect in Non-Small Cell Lung Cancer Therapy.
Mol Pharm
January 2025
Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi 221005, Uttar Pradesh, India.
Tyrosine kinase inhibitors have been employed for the treatment of lung cancer, owing to their role in regulating irregulated pathways or mutated genes. Bosutinib, a nonreceptor tyrosine kinase, has been recently investigated for lung cancer treatment. Bosutinib can also be used with paclitaxel as a combinatorial approach to receive a synergistic effect for the effective management of lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!